Tillotts Pharma AG To Acquire Global Rights for Entocort (budesonide) Outside The U.S. Under Agreement With AstraZeneca

Tillotts Pharma AG To Acquire Global Rights for Entocort (budesonide) Outside The U.S. Under Agreement With AstraZeneca
Rheinfelden, Switzerland based Tillotts Pharma AG (“Tillotts”), part of Japan’s Zeria Group, has announced its entry into an agreement in which it will acquire global rights from London based AstraZeneca to market the drug Entocort (budesonide), excluding the U.S., where Entocort will continue to be marketed by AstraZeneca. Tillotts is under agreement to expand and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *